DNA-demethylation by DAC induces MAGE expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsets

This publication has 32 references indexed in Scilit:

• Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma
  Biomedicine & Pharmacotherapy, 2019
• Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes
  Cancer Letters, 2017
• Clinical and biological effects of demethylating agents on solid tumours – A systematic review
  Cancer Treatment Reviews, 2017
• Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
  Cell, 2015
• DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
  Cell, 2015
• Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1
  Tumor Biology, 2014
• Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
  Cancer Cell, 2012
• MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing
  Cancer Immunology, Immunotherapy, 2011
• Inducible expression of a prostate cancer‐testis antigen, SSX‐2, following treatment with a DNA methylation inhibitor
  The Prostate, 2007
• Tolerability and safety of rituximab (MabThera®)
  Cancer Treatment Reviews, 2005